The NCI Genomic Data Commons As an Engine for Precision Medicine

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2017 Jun 11

PMID 28600341

Citations 137

Authors

Mark A Jensen

Vincent Ferretti

Robert L Grossman

Louis M Staudt

Affiliations

Soon will be listed here.

Abstract

The National Cancer Institute Genomic Data Commons (GDC) is an information system for storing, analyzing, and sharing genomic and clinical data from patients with cancer. The recent high-throughput sequencing of cancer genomes and transcriptomes has produced a big data problem that precludes many cancer biologists and oncologists from gleaning knowledge from these data regarding the nature of malignant processes and the relationship between tumor genomic profiles and treatment response. The GDC aims to democratize access to cancer genomic data and to foster the sharing of these data to promote precision medicine approaches to the diagnosis and treatment of cancer.

Citing Articles

High-Fidelity Long-Read Sequencing of an Avian Herpesvirus Reveals Extensive Intrapopulation Diversity in Tandem Repeat Regions.

Ortigas-Vasquez A, Bowen C, Renner D, Baigent S, Zhang Y, Yao Y bioRxiv. 2025; .

PMID: 39990410 PMC: 11844383. DOI: 10.1101/2025.02.10.637388.

A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective.

Kumar R, Joghee S Curr Treat Options Oncol. 2025; 26(1):1-13.

PMID: 39752094 DOI: 10.1007/s11864-024-01285-2.

Development and Validation of a Novel Four Gene-Pairs Signature for Predicting Prognosis in DLBCL Patients.

Tanabe A, Ndzinu J, Sahara H Int J Mol Sci. 2024; 25(23).

PMID: 39684518 PMC: 11640839. DOI: 10.3390/ijms252312807.

Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment.

Wang S, Zota V, Vincent M, Clossey D, Chen J, Cieslewicz M NPJ Precis Oncol. 2024; 8(1):278.

PMID: 39627379 PMC: 11614903. DOI: 10.1038/s41698-024-00774-9.

ASXL1 truncating variants in BOS and myeloid leukemia drive shared disruption of Wnt-signaling pathways but have differential isoform usage of RUNX3.

Lin I, Awamleh Z, Sinvhal M, Wan A, Bondhus L, Wei A BMC Med Genomics. 2024; 17(1):282.

PMID: 39614348 PMC: 11606099. DOI: 10.1186/s12920-024-02039-7.

References

Wilson W, Young R, Schmitz R, Yang Y, Pittaluga S, Wright G . Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015; 21(8):922-6. PMC: 8372245. DOI: 10.1038/nm.3884. View

Garraway L, Lander E . Lessons from the cancer genome. Cell. 2013; 153(1):17-37. DOI: 10.1016/j.cell.2013.03.002. View

Farrar J, Schuback H, Ries R, Wai D, Hampton O, Trevino L . Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Res. 2016; 76(8):2197-205. PMC: 4873364. DOI: 10.1158/0008-5472.CAN-15-1015. View

Landau D, Tausch E, Taylor-Weiner A, Stewart C, Reiter J, Bahlo J . Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574):525-30. PMC: 4815041. DOI: 10.1038/nature15395. View

Fan Y, Xi L, Hughes D, Zhang J, Zhang J, Futreal P . MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. Genome Biol. 2016; 17(1):178. PMC: 4995747. DOI: 10.1186/s13059-016-1029-6. View

Pui C, Yang J, Hunger S, Pieters R, Schrappe M, Biondi A . Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015; 33(27):2938-48. PMC: 4567699. DOI: 10.1200/JCO.2014.59.1636. View

Koboldt D, Zhang Q, Larson D, Shen D, McLellan M, Lin L . VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22(3):568-76. PMC: 3290792. DOI: 10.1101/gr.129684.111. View

Lawrence M, Stojanov P, Mermel C, Robinson J, Garraway L, Golub T . Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484):495-501. PMC: 4048962. DOI: 10.1038/nature12912. View

Ewing A, Houlahan K, Hu Y, Ellrott K, Caloian C, Yamaguchi T . Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nat Methods. 2015; 12(7):623-30. PMC: 4856034. DOI: 10.1038/nmeth.3407. View

10.

Forbes S, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J . COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2016; 45(D1):D777-D783. PMC: 5210583. DOI: 10.1093/nar/gkw1121. View

11.

Siu L, Lawler M, Haussler D, Knoppers B, Lewin J, Vis D . Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med. 2016; 22(5):464-71. PMC: 4995884. DOI: 10.1038/nm.4089. View

12.

Morin R, Johnson N, Severson T, Mungall A, An J, Goya R . Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010; 42(2):181-5. PMC: 2850970. DOI: 10.1038/ng.518. View

13.

Puente X, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-Subero J . Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015; 526(7574):519-24. DOI: 10.1038/nature14666. View

14.

Weston B, Hayden M, Roberts K, Bowyer S, Hsu J, Fedoriw G . Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(25):e413-6. DOI: 10.1200/JCO.2012.47.6770. View

15.

Larson D, Harris C, Chen K, Koboldt D, Abbott T, Dooling D . SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics. 2011; 28(3):311-7. PMC: 3268238. DOI: 10.1093/bioinformatics/btr665. View

16.

Ley T, Miller C, Ding L, Raphael B, Mungall A, Robertson A . Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-74. PMC: 3767041. DOI: 10.1056/NEJMoa1301689. View

17.

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

18.

Roberts K, Li Y, Payne-Turner D, Harvey R, Yang Y, Pei D . Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371(11):1005-15. PMC: 4191900. DOI: 10.1056/NEJMoa1403088. View

19.

Dang L, Su S . Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development. Annu Rev Biochem. 2017; 86:305-331. DOI: 10.1146/annurev-biochem-061516-044732. View

20.

Morin R, Mendez-Lago M, Mungall A, Goya R, Mungall K, Corbett R . Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476(7360):298-303. PMC: 3210554. DOI: 10.1038/nature10351. View